Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.

    Thumbnail
    Download
    Citations
    Altmetric
    Author
    Vaux, DL
    Date
    2009-10-29
    Source Title
    F1000 biology reports
    Publisher
    Faculty Opinions Ltd
    University of Melbourne Author/s
    Vaux, David
    Affiliation
    Medical Biology (W.E.H.I.)
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Vaux, D. L. (2009). Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.. F1000 Biol Rep, 1, pp.79-. https://doi.org/10.3410/B1-79.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/253577
    DOI
    10.3410/B1-79
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948278
    Abstract
    Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist 'Smac mimetic' compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced with analysis of how insect viruses stop host cells from killing themselves and led to the discovery of a family of proteins that regulate development in insects and signalling by tumour necrosis factor superfamily members in mammals, which prompted development of drugs that mimic natural IAP-binding proteins to promote cell death.

    Export Reference in RIS Format     

    Collections